Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)

San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)

52

No coordinating investigator defined.

Proteomics
Prostate and Urologic Cancers Research Group

To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, slow or rapid growth) and why there are differences in prostate cancer among men from different ethnic backgrounds.

We will expand and enhance our cohort of men at risk for prostate cancer by increasing enrollment of men at greater risk of prostate cancer and at a higher risk of high-grade prostate cancer. a. We will maintain follow-up and accrual of multi-ethnic, multi-racial cohort of men in the current SABOR cohort for prostate cancer outcomes b. Maintain collection of wide range of biologic samples for this cohort and perform validation studies as new biomarkers are identified. Biologics gathered on patient visits are serum (at enrollment, annually and cancer dx.), whole blood, buffy coat (enrollment and cancer dx.) and PSA (enrollment, annually, and cancer dx.). c. Maintain collection of extensive demographic and other risk factor data. Data elements gathered on cohort are date of birth, race, ethnicity, family history of PCA and other cancers, medical history, surgical history, current medications, AUA score, diabetes status, NSAID usage, prostate-related procedures and treatments d. Additional biologics will be collected for prospective biomarker studies. Examples may include post-DRE urine collections or blood specimens with specific processing requirements.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 6/2/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.